EchoNous Secures $60 Million in Funding from Kennedy Lewis Investment Management

VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Are Commercially Available in the U.S.

With the launch of our VenSure Balloon Sinus Dilation System and Cube 4D Navigation system with VirtuEye, “Intersect ENT is transforming to become a more diversified, integrated and evidence-based growth company participating across the continuum of care in CRS,” said Thomas A. West, President and Chief Executive Officer of Intersect ENT.

International Experts Call for a Unified Public Health Response to NAFLD and NASH Epidemic

Patients with obesity or type 2 diabetes are at a higher risk of developing NAFLD and NASH.

EchoNous, the leader in portable AI-guided ultrasound tools and software, announced it has raised $60 million in funding from Kennedy Lewis Investment Management (“Kennedy Lewis”), a leading opportunistic credit manager with a strong track record of supporting innovative life sciences companies.

The investment from Kennedy Lewis combines senior secured debt and equity and builds on the support of KKR, which has been EchoNous’ principal investor since 2015.

Proceeds from the financing will help fuel the commercial launch of Kosmos, EchoNous’ flagship device. Kosmos is the first AI-guided point-of-care ultrasound (POCUS) system to provide diagnostic-quality imaging on par with larger, less portable, and more expensive imaging machines. Kosmos’ system enables systolic heart function assessment, and it is the only handheld POCUS device to offer continuous-wave Doppler capability, a feature with important applications for cardiology. In addition, Kosmos is the only product of its size and in its category to meet HIPAA requirements for data collection, storage, and transmission.

Rich Gumer, Managing Director at Kennedy Lewis and head of the firm’s Life Sciences strategy, said: “We are thrilled to partner with EchoNous on its next phase of growth. EchoNous has an exceptional track record in developing high quality AI-guided ultrasound devices which are more intelligent, accessible, and easier to use. Kosmos’ superior imaging quality, mobility and affordability have the potential to significantly improve patient care and lower healthcare costs which are the core tenets of Kennedy Lewis’ investment ethos in life sciences.”

“This investment marks a turn toward an exciting future for POCUS in which clinical bedside medicine is driven by higher-performance ultrasound technologies that are easy to implement and cost effective,” added Kevin Goodwin, CEO of EchoNous. “To make this vision a reality, we value experienced partners who can see that future as clearly as we do. We could not be happier to have Kennedy Lewis’ support.”

spot_img

DON'T MISS

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.